ATUS reported a top-line contraction year over year in the fourth quarter of 2024, owing to declining net sales in multiple segments.

West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.

OGE's fourth-quarter revenues beat the Zacks Consensus Estimate by 13.1%. The top line also increases 34.2% from the year-ago level.

FLS' fourth-quarter 2024 revenues increase 1.3% year over year, driven by the impressive performance of its Flowserve Flow Control Division unit.

KGC produces 514,355 gold equivalent ounces in the fourth quarter, down 5.9% year over year.

ESI sees strong growth in the Electronics segment in the fourth quarter, driving its top line.

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

DUK's fourth-quarter 2024 earnings beat estimates, and revenues increase year over year.

CW's total sales in the fourth quarter of 2024 surpass the Zacks Consensus Estimate by 4.9%. The top line also increases 4.9% from the year-ago level.

STWD's fourth-quarter 2024 results are likely to reflect year-over-year declines in earnings and revenues.